PAMP
CORT icon

Polar Asset Management Partners’s Corcept Therapeutics CORT Stock Holding History

Polar Asset Management Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-32,980
Closed -$555K – 612
2020
Q2 		$555K Buy
+32,980
New +$463K 0.01% 351

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Polar Asset Management Partners's CORT Position: Q3 2020 in Review

Polar Asset Management Partners sold out of Corcept Therapeutics (CORT) in Q3 2020, closing a stake of 32,980 shares — an estimated $555K sold.

Polar Asset Management Partners first reported a position in CORT in Q2 2020 and held it in 1 quarter. The position peaked at $555K in Q2 2020. 223 funds tracked by Wall St. Rank hold CORT as of Q3 2020.

  • Polar Asset Management Partners reported no remaining Corcept Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Polar Asset Management Partners sold 32,980 Corcept Therapeutics shares in Q3 2020, an estimated $555K.
  • Polar Asset Management Partners first reported a position in Corcept Therapeutics in Q2 2020 and held it in 1 quarter.
  • Polar Asset Management Partners's Corcept Therapeutics position peaked at $555K in Q2 2020.
  • 223 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2020.

Based on Polar Asset Management Partners's 13F filing for Q3 2020, filed 16 Nov 2020.